eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2026-06-25 23 2 59291 article Amol Tonde 1 Santosh Chhajed 1 Department of Pharmaceutical Chemistry, MET’s Institute of Pharmacy, Savitribai Phule Pune University, Nashik, India In genetically susceptible individuals, gluten intake leads to celiac disease (CD), a chronic immune-related enteropathy that results in villous atrophy, intestinal inflammation, and malabsorption. It marks roughly 0.7%–1.4% of the global populace, with occurrence growing over time. Presently, the single accepted cure is a strict, lifelong gluten-free diet (GFD); nevertheless, this approach is hard to manage, carries risks of hidden gluten exposure, and cannot wholly alleviate symptoms or prevent intestinal impairment in all patients. Recent developments have driven the progress of several emerging therapeutic strategies. These comprise gluten-degrading enzymes designed to detoxify immunogenic peptides, pharmacological agents such as tight-junction regulators and transglutaminase inhibitors that target intestinal permeability and antigen modification, as well as immune-modulating therapies aimed at reducing pathological immune responses. Additionally, microbiome-based interventions are being explored to restore gut homeostasis and support immune regulation. Nutraceuticals and vaccine-based methods are two complementary therapies that are being researched. This review emphasizes an executive summary of the background and pathophysiology of celiac disease, highlights the limitations of the GFD, and focuses on recent advancements in enzyme therapy, pharmacological treatments, and immunotherapies. Furthermore, it discusses ongoing clinical trials (CT) and future perspectives, emphasizing the potential of these novel approaches to transform disease management beyond dietary restriction. https://www.biotech-asia.org/vol23no2/emerging-pharmacological-and-immunotherapeutic-strategies-in-celiac-disease-from-mechanisms-to-clinical-translation/ Celiac disease; Emerging therapies; Enzyme therapy; Gluten Immunotherapy; Pharmacological treatment; Transglutaminase inhibitors